Nurix
Scientist I, Medicinal Chemistry
The Woodlands, Texas. Posted a month ago
The role
You will design and synthesize novel small molecules for patients with unmet medical needs. You will work as part of a multidisciplinary project team using structure-based drug design.
What you will do
- Design and synthesize novel chemical entities optimized for potency, selectivity, pharmacokinetics, and in vivo efficacy
- Engage in rational structure-based drug discovery
- Apply problem-solving skills to troubleshoot challenges and identify practical solutions
- Design and execute high-quality experiments and analyze results
- Advance structure-activity relationship (SAR) studies
- Collaborate with scientists in computational chemistry, structural biology, biochemistry, biophysics, cellular biology, pharmacology, DMPK, and toxicology
- Stay current with advances in synthetic and medicinal chemistry
- Communicate scientific rationale, results, challenges, and recommendations to colleagues and cross-functional teams
Required qualifications
- PhD with up to 4 years of relevant experience, MS with 6 or more years of relevant experience, or BS or equivalent with 10 or more years of relevant experience
- Strong expertise in synthetic organic chemistry
- Demonstrated ability to design and execute complex, multistep organic synthesis
- Strong scientific and synthetic problem-solving skills
- Ability to independently troubleshoot challenging chemistry
- Scientific curiosity and creativity
- Ability to rapidly learn and apply new concepts, technologies, and approaches
- Strong interpersonal and teamwork skills
- Ability to contribute in a collaborative, multidisciplinary research environment
- Excellent written and verbal communication skills
- Knowledge of medicinal chemistry principles, structure-based drug design, pharmacology, and/or ADME/PK
About the company
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines. The company aims to establish degrader-based treatments for cancer and inflammatory diseases.